Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
Baxter
Harvard Business School
Colorcon
Dow

Last Updated: November 20, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021129

See Plans and Pricing

« Back to Dashboard

NDA 021129 describes NEURONTIN, which is a drug marketed by Pfizer Pharms and Parke Davis and is included in three NDAs. It is available from three suppliers. There is one patent protecting this drug. Additional details are available on the NEURONTIN profile page.

The generic ingredient in NEURONTIN is gabapentin. There are twenty-nine drug master file entries for this compound. Eighty-two suppliers are listed for this compound. Additional details are available on the gabapentin profile page.
Summary for 021129
Tradename:NEURONTIN
Applicant:Parke Davis
Ingredient:gabapentin
Patents:1
Formulation / Manufacturing:see details
Pharmacology for NDA: 021129
Suppliers and Packaging for NDA: 021129
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
NEURONTIN gabapentin SOLUTION;ORAL 021129 NDA Parke-Davis Div of Pfizer Inc 0071-2012 0071-2012-23 470 mL in 1 BOTTLE (0071-2012-23)
NEURONTIN gabapentin SOLUTION;ORAL 021129 NDA AUTHORIZED GENERIC Greenstone LLC 59762-5025 59762-5025-1 470 mL in 1 BOTTLE, GLASS (59762-5025-1)
Paragraph IV (Patent) Challenges for 021129
Tradename Dosage Ingredient NDA Submissiondate
NEURONTIN SOLUTION;ORAL gabapentin 021129

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;ORALStrength250MG/5ML
Approval Date:Mar 2, 2000TE:AARLD:Yes
Patent:  Start TrialPatent Expiration:Nov 28, 2022Product Flag?Substance Flag?Delist Request?Y

Expired US Patents for NDA 021129

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Parke Davis NEURONTIN gabapentin SOLUTION;ORAL 021129-001 Mar 2, 2000   Start Trial   Start Trial
Parke Davis NEURONTIN gabapentin SOLUTION;ORAL 021129-001 Mar 2, 2000   Start Trial   Start Trial
Parke Davis NEURONTIN gabapentin SOLUTION;ORAL 021129-001 Mar 2, 2000   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Merck
AstraZeneca
Baxter
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.